These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 23269354

  • 1. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B, Haller H, Mrklić I, Košta V, Čarić A, Tomić S.
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [Abstract] [Full Text] [Related]

  • 6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP.
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
    Sundov D, Petric Mise B, Mrklic I, Bacic B, Vrdoljak E, Tomic S.
    Neoplasma; 2017 Jan; 64(2):289-298. PubMed ID: 28052682
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
    Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS.
    Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
    Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH.
    Pathol Int; 2006 Feb; 56(2):62-70. PubMed ID: 16445817
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H.
    Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
    [Abstract] [Full Text] [Related]

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
    Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ.
    Clin Cancer Res; 2004 Aug 15; 10(16):5546-53. PubMed ID: 15328195
    [Abstract] [Full Text] [Related]

  • 14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 15. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
    Dian D, Brüning A, Mylonas I.
    Arch Gynecol Obstet; 2011 Aug 01; 284(2):437-43. PubMed ID: 20803206
    [Abstract] [Full Text] [Related]

  • 16. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R, Feng J, Fang XZ, Bai F, Cheng YX, Liu C, Zhu W, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul 01; 41(7):459-63. PubMed ID: 17083811
    [Abstract] [Full Text] [Related]

  • 17. ErbB-3 predicts survival in ovarian cancer.
    Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.
    J Clin Oncol; 2006 Sep 10; 24(26):4317-23. PubMed ID: 16896008
    [Abstract] [Full Text] [Related]

  • 18. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
    Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Janssen EA, Baak JP, Rollason TP.
    Int J Gynecol Pathol; 2008 Apr 10; 27(2):191-8. PubMed ID: 18317224
    [Abstract] [Full Text] [Related]

  • 19. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec 10; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer.
    Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M.
    Jpn J Clin Oncol; 2010 Jul 10; 40(7):670-6. PubMed ID: 20382636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.